ImmunoPrecise Antibodies Ltd. (IPA)

ImmunoPrecise Antibodies Revenue

In the fiscal year ending April 30, 2025, ImmunoPrecise Antibodies had annual revenue of 24.52M CAD with 0.01% growth. ImmunoPrecise Antibodies had revenue of 6.98M in the quarter ending April 30, 2025, with 8.08% growth.

• Revenue (ttm): 24.52M CAD
• Revenue Growth: +0.01%
• P/S Ratio: 3.74
• Revenue / Employee: 240,392 CAD
• Employees: 102
• Market Cap: 90.46M USD

Revenue Chart

* This company reports financials in CAD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Apr 30, 2025	24.52M	2.00K	0.01%
Apr 30, 2024	24.52M	3.85M	18.65%
Apr 30, 2023	20.67M	1.30M	6.72%
Apr 30, 2022	19.36M	1.45M	8.11%
Apr 30, 2021	17.91M	3.85M	27.42%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.